Skip to content

Net margin at other companies

Ionis Pharmaceuticals logo
Ionis PharmaceuticalsIONS
-30.9%-10.5pp
Biogen logo
BiogenBIIB
14.3%-0.8pp
Acadia Pharmaceuticals logo
Acadia PharmaceuticalsACAD
34.3%+11.3pp
Ultragenyx Pharmaceutical logo
Ultragenyx PharmaceuticalRARE
-90.9%-2.1pp
uniQure logo
uniQureQURE
-1,154.4%+89.3pp
Precigen logo
PrecigenPGEN
-3,656%

Other financials

Income statement

See full
Revenue--100%
Operating income-$43.5M-103%
Net income-$42.4M-97.0%
EPS (diluted)-$0.12-50.0%

Balance sheet

See full
Cash & equivalents$276.6M+137%
Total debt$68.6M+11.2%
Total equity$211.9M+285%
Total assets$300.4M+117%

Cash flow

See full
Operating cash flow-$40.9M-85.6%
CapEx$24.0K-93.7%
Free cash flow-$40.9M-82.6%

Valuation

See full
Market cap$1.97B+351%
Enterprise value$1.76B+368%
P/S263.9×+203×

Profitability

See full
Operating margin-1,774.4%+1,437pp
FCF margin-1,503.6%+621pp

Returns & leverage

See full
Return on equity-97.3%-27.3pp
Debt / equity0.3×-0.8×
Current ratio14×+8.7×

Where this comes from

Calculated from Taysha Gene Therapies, Inc.’s reported figures.

Based on trailing twelve months.

The official record: Taysha Gene Therapies, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Taysha Gene Therapies, Inc.'s net margin.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Taysha Gene Therapies, Inc.'s net margin?
Taysha Gene Therapies, Inc. (TSHA) reported net margin of -1,738.4% in Q1 2026.
How has Taysha Gene Therapies, Inc.'s net margin changed year-over-year?
Taysha Gene Therapies, Inc.'s net margin decreased by 44.7% year-over-year, from -1,201.1% to -1,738.4%.
What is the long-term trend for Taysha Gene Therapies, Inc.'s net margin?
Over 2 years (2022 to 2025), Taysha Gene Therapies, Inc.'s net margin has grown at a -59.0% compound annual growth rate (CAGR), from -6,635.3% to -1,115.3%.
What does net margin mean?
Net income as a percentage of revenue (trailing twelve months). The bottom-line profitability measure after all costs, interest, and taxes.